Trial Profile
Phase I Study of MEK Inhibitor Selumetinib in Combination With Azacitidine in Patients With Higher Risk Chronic Myeloid Neoplasia: MDS, MDS/MPNs, and Myelofibrosis
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 02 Feb 2024
Price :
$35
*
At a glance
- Drugs Azacitidine (Primary) ; Selumetinib (Primary)
- Indications Myelofibrosis; Myeloid leukaemia
- Focus Adverse reactions
- 25 Jan 2024 Planned primary completion date changed from 4 Sep 2023 to 4 Sep 2025.
- 06 Jun 2023 Trial design presented at the 59th Annual Meeting of the American Society of Clinical Oncology
- 12 May 2021 Planned End Date changed from 4 Sep 2023 to 4 Sep 2025.